Conform to the result from Lizard-nacol et al., (1999) which found that GSTM1 gene polymorphism did not associate with clinicopathology characteristics, clinical outcomes of chemotherapeutic agents in advanced breast cancer. This evidence concerns the gene GSTM1 and breast carcinoma.